Advocacy Week 2026: State
The Solve ME/CFS Initiative (Solve M.E.) provides a free webinar series to educate patients, researchers, and healthcare providers, as well as to raise awareness of ME/CFS, Long Covid, and ‘long-haul’ diseases among scientists, political leaders, and the general public.
The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog & Fatigue in People with Long Covid
Dr. Michael Peluso, Dr. Penny Markham, and Ezra Spier discuss the ADDRESS-LC trial, how the lived experience of patients has informed its development and conduct, and the importance of patient-researcher collaboration.
Pacing: Power In Slowing Down (EmPOWER M.E. 2025)
Pacing is one of the most talked-about — but often misunderstood — tools in chronic illness management. In this informative session, we break down what pacing really means, why it works, and how it works, so no family has to learn the hard way.
Immune Dysfunction & T-Cell Exhaustion via Single Cell Immune Profiling in ME/CFS & Long Covid
Scientists and patient representatives from the Selin Lab and HiFiBiO Therapeutics discuss their study of dysregulated immune cells in ME/CFS and Long Covid patients and the pursuit of diagnostic biomarkers and therapeutic innovations.
The ADDRESS-LC Trial: Studying the Impact of Bezisterim on Brain Fog & Fatigue in People with Long Covid
Dr. Michael Peluso, Dr. Penny Markham, and Ezra Spier discuss the ADDRESS-LC trial, how the lived experience of patients has informed its development and conduct, and the importance of patient-researcher collaboration.
Pacing: Power In Slowing Down (EmPOWER M.E. 2025)
Pacing is one of the most talked-about — but often misunderstood — tools in chronic illness management. In this informative session, we break down what pacing really means, why it works, and how it works, so no family has to learn the hard way.
The Solve ME/CFS Initiative (Solve M.E.) provides a free webinar series to educate patients, researchers, and healthcare providers, as well as to raise awareness of ME/CFS, Long Covid, and ‘long-haul’ diseases among scientists, political leaders, and the general public.
